NCT03370302 2023-02-08A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological MalignanciesCalithera Biosciences, IncPhase 1 Terminated28 enrolled 33 charts